SLN-124 is under clinical development by Silence Therapeutics and currently in Phase I for Beta Thalassaemia. According to GlobalData, Phase I drugs for Beta Thalassaemia have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SLN-124’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SLN-124 overview
Silence Therapeutics overview
Silence Therapeutics, formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company’s pipeline products include SLN124, and SLN360. Its SLN360 is developed for the treatment of cardiovascular disease with high Lp(a) in risk of heart disease and heart stroke, and SLN124 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interface that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany, the US, and the UK. Silence Thrapeutics is headquartered in London, Greater London, the UK.
For a complete picture of SLN-124’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.